Form 4 for SPRY ARS Pharmaceuticals, Inc.
Accepted 2022-12-01 00:00:00 ET · period of report 2022-11-29 · accession 0001209191-22-059187 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2022-12-01 | 2022-11-29 | SPRY | Scott Kathleen D. | CFO | P - Purchase | $6.24 | +8,250 | 8,250 | New | +$51.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-29 | P | A | 8,250 | $6.24 | 8,250 | I See footnote | — | — | (F1) The price reported in Column 4 is the weighted average price. The shares were sold in multiple transactions at prices ranging from $6.16 to $6.26, inclusive. Upon request by the Securities and Exchange Commission staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. (F2) By Scott 2008 Trust Dated 3/28/08. |